Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Clinical trial NCT03941236 · COMPLETED

Trial details

NCT number: NCT03941236
Sponsor: Zealand Pharma
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Congenital Hyperinsulinism

Start date: 2019-05-02
Primary completion: 2025-01-28
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.